Hide metadata

dc.contributor.authorDougados, Maxime
dc.contributor.authorBrault, Yves
dc.contributor.authorLogeart, Isabelle
dc.contributor.authorvan der Heijde, Désirée
dc.contributor.authorGossec, Laure
dc.contributor.authorKvien, Tore
dc.date.accessioned2015-10-20T10:52:12Z
dc.date.available2015-10-20T10:52:12Z
dc.date.issued2012
dc.identifier.citationArthritis Research & Therapy. 2012 May 30;14(3):R129
dc.identifier.urihttp://hdl.handle.net/10852/46978
dc.description.abstractIntroduction The Rheumatoid Arthritis Impact of Disease (RAID) is a patient-reported outcome measure evaluating the impact of rheumatoid arthritis (RA) on patient quality of life. It comprises 7 domains that are evaluated as continuous variables from 0 (best) to 10 (worst). The objective was to define and identify cut-off values for disease activity states as well as improvement scores in order to present results at the individual level (for example, patient in acceptable state, improved patient). Methods Patients with definite active RA requiring anti-tumour necrosis factor (anti-TNF) therapy were seen at screening, baseline and after 4 and 12 weeks of etanercept therapy. Answers to "Gold standard" questions on improvement (MCII: Minimum Clinically Important Improvement) and an acceptable status (PASS: Patient Acceptable Symptom State) were collected as well as the RAID score and Disease Activity Score 28- erythrocyte sedimentation rate (DAS28-ESR). Cut-offs were defined by different techniques including empirical, measurement error and gold standard anchors. The external validity of these cut-offs was evaluated using the positive likelihood ratio (LR) based on the patient's perspective (for example, patient's global) and on low disease activity status (such as DAS28-ESR). Results Ninety-seven (97) of the 108 recruited patients (age: 54 ± 13 years old, female gender: 75%, rheumatoid factor positive: 81%, disease duration: 8 ± 7 years, CRP: 18 ± 30 mg/l, DAS28-ESR: 5.4 ± 0.8) completed the 12 weeks of the study. The different techniques suggested thresholds ranging from 0.2 to 3 (absolute change) and from 6 to 50% (relative change) for defining MCII and thresholds from less than 1 to less than 4.2 for defining PASS. The evaluation of external validity (LR+) showed the highest LR+ was obtained with thresholds of 3 for absolute change; 50% for relative change and less than 2 for an acceptable status. Conclusions This study showed that thresholds defined for continuous variables are closely related to the methodological technique, justifying a systematic evaluation of their validity. Our results suggested that a change of at least 3 points (absolute) or 50% (relative) in the RAID score should be used to define a MCII and that a maximal value of 2 defines an acceptable status. Trial Registration Clinicaltrial.gov: NCT004768053
dc.language.isoeng
dc.rightsDougados et al.; licensee BioMed Central Ltd.
dc.rightsAttribution 2.0 Generic
dc.rights.urihttp://creativecommons.org/licenses/by/2.0/
dc.titleDefining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID)
dc.typeJournal article
dc.date.updated2015-10-20T10:52:12Z
dc.creator.authorDougados, Maxime
dc.creator.authorBrault, Yves
dc.creator.authorLogeart, Isabelle
dc.creator.authorvan der Heijde, Désirée
dc.creator.authorGossec, Laure
dc.creator.authorKvien, Tore
dc.identifier.doihttp://dx.doi.org/10.1186/ar3859
dc.identifier.urnURN:NBN:no-51131
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/46978/1/13075_2012_Article_3624.pdf
dc.type.versionPublishedVersion
cristin.articleidR129


Files in this item

Appears in the following Collection

Hide metadata

Attribution 2.0 Generic
This item's license is: Attribution 2.0 Generic